<DOC>
	<DOCNO>NCT02105636</DOCNO>
	<brief_summary>The purpose study find whether Nivolumab significantly improve overall survival compare therapy investigator 's choice patient recurrent metastatic head neck carcinoma .</brief_summary>
	<brief_title>Trial Nivolumab v Therapy Investigator 's Choice Recurrent Metastatic Head Neck Carcinoma ( CheckMate 141 )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Men woman ≥ 18 year age Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 1 Histologically confirm recurrent metastatic SCCHN ( oral cavity , pharynx , larynx ) , stage III/IV amenable local therapy curative intent ( surgery radiation therapy without chemotherapy ) Tumor progression recurrence within 6 month last dose platinum therapy adjuvant ( ie radiation surgery ) , primary ( ie , radiation ) , recurrent , metastatic set Measurable disease Computed tomography ( CT ) Magnetic resonance imaging ( MRI ) per Response Evaluation Criteria In Solid Tumors ( RECIST 1.1 ) criterion Active brain metastasis leptomeningeal metastasis allow Histologically confirm recurrent metastatic carcinoma nasopharynx , squamous cell carcinoma unknown primary , salivary gland nonsquamous histology ( eg : mucosal melanoma ) allow Subjects active , know suspected autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>